Disc Medicine Expands Access to Bitopertin for Rare Porphyria Patients Ahead of Phase 3 Data
Event summary
- Disc Medicine launched an expanded access program (EAP) for bitopertin, targeting EPP and XLP patients in the U.S.
- Bitopertin is currently in Phase 3 APOLLO trial, with topline data expected in Q4 2026.
- FDA decision on bitopertin is anticipated by mid-2027, following potential CRL response submission.
- EAP available for EPP patients aged 12+ who lack satisfactory therapeutic alternatives.
- Disc licensed bitopertin globally from Roche in May 2021.
The big picture
Disc Medicine's expanded access program for bitopertin reflects strategic urgency in addressing unmet needs for EPP patients while navigating the final stages of regulatory approval. The move comes as the company positions itself in the competitive rare disease space, where successful Phase 3 data could validate its GlyT1 inhibition platform. The FDA decision timeline will be critical in determining Disc's commercialization window and potential market differentiation.
What we're watching
- Regulatory Timeline
- Whether Disc can maintain its mid-2027 FDA decision timeline following APOLLO data release in Q4 2026.
- Clinical Efficacy
- How Phase 3 APOLLO trial results will compare to earlier BEACON and AURORA trials.
- Market Positioning
- The pace at which Disc can establish bitopertin as a potential first disease-modifying therapy for EPP.
Related topics